

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Attorney Docket No.
Timo Kars van den Berg et al.	)	080743235001
Serial No.:	)	
10/007,275	)	
Filed:	)	
October 26, 2001	)	
For:	)	
METHOD FOR INHIBITING CELL	)	
FUNCTIONING FOR USE IN ANTI-	)	
INFLAMMATORY AND ANTI-	)	
TUMOR THERAPIES	)	
Examiner:	)	
Yaen, Christopher H.	)	
Group Art Unit:	)	
1642	)	
Confirmation No.:	)	
5284	)	

RECEIVED  
MAR 11 2004  
TECH CENTER 1600/2900

AMENDMENTS TO THE CLAIMS

Claim 1 (Currently Amended)      A method for inhibiting cell functioning as a target for use in anti-inflammatory therapies and in treating myeloid leukemia in the body ~~and anti-tumor therapies in the body~~ of a warm-blooded living being, which comprises administering to said being a drug comprising, in a quantity effective for said therapies, a substance that specifically recognizes the extracellular domain of SIRP (anti-SIRP substance) and that inhibits the functioning of macrophages ~~macrophages~~ by suppressing their activation by a factor of at least 10 as measured by each of the following macrophage ~~macrophage~~ activity tests: (i) the production of nitric oxide (NO), (ii) the production of reactive oxygen species, and (iii) the production of tumor necrosis factor-alpha (TNF- $\alpha$ ), said anti-SIRP substance being selected from Fab-fragments of monoclonal antibodies and (bio) chemically modified products of such fragments wherein the intended anti-SIRP activity has been maintained ~~pathologic myeloid cells~~.

Claims 2-7 (Cancelled)

Claim 8 (Currently amended)      The method as claimed in claim 1-7, wherein said anti-SIRP substance is a Fab-fragment of monoclonal antibody ED9 or ED17, or said modified product thereof.

Claims 9 and 10 (Cancelled)

Claims 11-14 (Withdrawn)